Ratings Exscientia plc

Equities

EXAI

US30223G1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
4.69 ^USD	-0.85%		-9.81%	-26.83%

May. 21	Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon	MT
May. 21	Exscientia to Reduce Up to 25% Workforce by Year End	MT

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
EXSCIENTIA PLC	-26.83%	593M	-
MODERNA, INC.	+67.53%	63.85B	B-
IQVIA HOLDINGS INC.	-0.77%	41.83B	B
LONZA GROUP AG	+45.66%	40.65B	A
CELLTRION, INC.	-10.72%	27.12B	C
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B	B
BIO-TECHNE CORPORATION	+4.70%	12.73B	B+
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B	B+
MEDPACE HOLDINGS, INC.	+27.41%	12.07B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes